505084-55-9

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-5-(trifluoromethyl)-4-iodopyridine is used as a key intermediate in the synthesis of pyridine-2,4-diamine derivatives, which serve as focal adhesion kinase (FAK) inhibitors. These FAK inhibitors are crucial for the treatment of various conditions, including arthritis, inflammatory disorders, and immune system-related diseases. 2-chloro-5-(trifluoromethyl)-4-iodopyridine's unique structure allows for the development of targeted therapies that can potentially alleviate symptoms and improve the quality of life for patients suffering from these conditions.

InChI:InChI=1/C6H2ClF3IN/c7-5-4(11)1-3(2-12-5)6(8,9)10/h1-2H

Upstream product

• 52334-81-3 2-chloro-5-trifluoromethylpyridine 

Downstream Products

• 505084-58-2 2-chloro-5-(trifluoromethyl)pyridine-4-carboxylic acid 
• 505084-57-1 2-chloro-5-(trifluoromethyl)pyridine-4-carbaldehyde 
• 796090-24-9 6-chloro-3-(trifluoromethyl)pyridine-2-carboxylic acid 
• 1061358-71-1 2-((2-chloro-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide 
• 1290608-32-0 2-(2-chloro-5-(trifluoromethyl)pyridin-4-ylamino)-6-methoxy-N-methylbenzamide 
• 1201935-97-8 2-(2-chloro-5-(trifluoromethyl)pyridin-4-ylamino)-5-fluoro-N-methoxybenzamide 
• 1206597-48-9 2-chloro-4-(4-fluorophenyl)-5-(trifluoromethyl)pyridine 
• 1372799-99-9 2-(2-chloro-5-(trifluoromethyl)pyridin-4-ylamino)-4-fluoro-N-methylbenzamide 
• 1201934-93-1 2-[[2-[(2,5-dimethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-6-methoxy-N-methyl-benzamide 
• 1201935-26-3 2-[[2-[(2,5-dimethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-5-fluoro-N-methoxy-benzamide 
• 1201934-66-8 N-methyl-2-[[2-[(2-methylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]benzamide 
• 1201934-67-9 2-[[2-[(2,5-dimethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201933-76-7 2-((2-((1,5-dimethylpyrazol-3-yl)amino)-5-(trifluoromethyl)-4-pyridyl)amino)-N-methyl-benzamide 
• 1201934-88-4 2-[[2-[(1,3-dimethylpyrazol-4-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methoxy-benzamide 

Relevant academic research and scientific papers

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

2-AMINO SUBSTITUTED PYRIDINE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a 2-amino substituted pyridine derivative useful as an active ingredient of medicines such as antipsychotic agent, anti-anxiety agent, or brain function improver. SOLUTION: The present invention provides a compound represe

INHIBITORS OF FOCAL ADHESION KINASE

The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.

Recommendable routes to trifluoromethyl-substituted pyridine- and quinolinecarboxylic acids

As part of a case study, rational strategies for the preparation of all ten 2-, 3-, or 4-pyridinecarboxylic acids and all nine 2-, 3-, 4-, or 8-quinolinecarboxylic acids bearing trifluoromethyl substituents at the 2-, 3-, or 4-position were elaborated. The trifluoromethyl group, if not already present in the precursor, was introduced either by the deoxygenative fluorination of suitable carboxylic acids with sulfur tetrafluoride or by the displacement of ring-bound bromine or iodine by trifluoromethylcopper generated in situ. The carboxy function was produced by treatment of organolithium or organomagnesium intermediates, products of halogen/metal or hydrogen/ metal permutation, with carbon dioxide. ( Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003).